In August 2025, InSilico Medicine Hong Kong Limited announced a clinical trial is to learn about INS018_055 in adults with ...

Key Points Revenue grew 10% year-over-year to $10.8 million (GAAP) in Q2 2025, reflecting continued top-line gains, with GAAP net revenues of $10.8 million. Adjusted diluted earnings per share ...

MannKind saw decent growth from its two core products in Q2 and just signed a new non-dilutive financing agreement with ...

Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readoutsAleniglipron clinical development program expanded to optimize ...

GRI-0621 appears to reduce markers of fibrosis in people with idiopathic pulmonary fibrosis, interim clinical trial data ...

Contineum Therapeutics has pumped the brakes on two projects, freeing up resources to go full speed ahead in its pursuit of Bristol Myers Squibb in idiopathic pulmonary fibrosis.

A new AI tool helps predict survival in fibrotic lung disease, outperforming traditional clinical and imaging methods in a study of over 1,200 patients.

"We are extremely excited about forming this important collaboration between our companies and scientists that will empower ...

Q2 2025 Earnings Call Transcript August 4, 2025 Syndax Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0 ...